B-MS's muraglitazer rights returned

9 January 2006

US drug majors Bristol-Myers Squibb and Merck & Co have reached a mutually-acceptable termination agreement, with all rights to muraglitazar, an investigational oral drug for the treatment of type 2 diabetes, returning to the former as of December 21, 2005. The termination agreement also covers the reversion to B-MS of a back-up compound to muraglitazar.

B-MS is continuing discussions with the US Food and Drug Administration and is considering a range of options including conducting further studies or terminating development of muraglitazar. The additional trials could take about five years to complete, it says.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight